Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 6 56-6, 2004, Pages

  Chen, Yinghong ^a   Epperson, Sara ^a   Makhsudova, Lala ^a   Ito, Bruce ^b   Suarez, Jorge ^a   Dillmann, Wolfgang ^a   Villarreal, Francisco ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Metabasis Therapeutics Inc   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

Collagen deposition; Extracellular matrix; Remodeling

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDROFURAN 2 YL) 9H PURIN 2 YL]PROP 2 YNYL]CYCLOHEXYLMETHYL ESTER; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR STIMULATING AGENT; ATL 193; IODOTUBERCIDIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; VIRUS RECOMBINANT;

2-CHLOROADENOSINE; ADENOSINE KINASE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANIMALS; CELL DIVISION; CELLS, CULTURED; COLLAGEN; CYCLIC AMP; EXTRACELLULAR MATRIX; FIBROBLASTS; GENE EXPRESSION; GENE SILENCING; HEART VENTRICLES; LEUCINE; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; THYMIDINE; TRITIUM; VASODILATOR AGENTS;

EID: 9344260296     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00217.2004     Document Type: Article

References (35)

1. Alexander SP, Cooper J, Shine J, and Hill SJ. Characterization of the human brain putative A2B adenosine receptor expressed in Chinese hamster ovary (CHO. A2B4) cells. Br J Pharmacol 119: 1286-1290, 1996.
2. Auchampach JA, Jin X, Wan TC, Caughey GH, and Linden J. Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol Pharmacol 52: 846-860, 1997.
3. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, and Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89: 151-163, 1994.
4. Bouma MG, Stad RK, van den Wildenberg FA, and Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153: 4159-4168, 1994.
5. Brackett LE and Daly JW. Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharmacol 47: 801-814, 1994.
6. Dubey RK, Gillespie DG, and Jackson EK. Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. Hypertension 31: 943-948, 1998.
7. Dubey RK, Gillespie DG, Mi Z, and Jackson EK. Cardiac fibroblasts express the cAMP-adenosine pathway. Hypertension 36: 337-342, 2000.
8. Dubey RK, Gillespie DG, Mi Z, and Jackson EK. Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension 37: 1095-1100, 2001.
9. Dubey RK, Gillespie DG, Mi Z, and Jackson EK. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96: 2656-2666, 1997.
10. Dubey RK, Gillespie DG, Zacharia LC, Mi Z, and Jackson EK. A(2b) receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. Hypertension 37: 716-721, 2001.
11. Dubey RK, Mi Z, Gillespie DG, and Jackson EK. Cyclic AMP-adenosine pathway inhibits vascular smooth muscle cell growth. Hypertension 28: 765-771, 1996.
12. Feoktistov I and Biaggioni I. Adenosine A2B receptors. Pharmacol Rev 49: 381-402, 1997.
13. Feoktistov I and Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96: 1979-1986, 1995.
14. Feoktistov I and Biaggioni I. Characterization of adenosine receptors in human erythroleukemia cells and platelets: further evidence for heterogeneity of adenosine A2 receptor subtypes. Mol Pharmacol 43: 909-914, 1993.
15. Feoktistov I and Biaggioni I. Pharmacological characterization of adenosine A2B receptors: studies in human mast cells co-expressing A2A and A2B adenosine receptor subtypes. Biochem Pharmacol 55: 627-633, 1998.
16. Feoktistov I, Murray JJ, and Biaggioni I. Positive modulation of intracellular Ca2+ levels by adenosine A2b receptors, prostacyclin, and prostaglandin E1 via a cholera toxin-sensitive mechanism in human erythroleukemia cells. Mol Pharmacol 45: 1160-1167, 1994.
17. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, and Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 362: 364-374, 2000.
18. Gnudi L, Frevert EU, Houseknecht KL, Erhardt P, and Kahn BB. Adenovirus-mediated gene transfer of dominant negative ras(asn17) in 3T3L1 adipocytes does not alter insulin-stimulated P13-kinase activity or glucose transport. Mol Endocrinol 11: 67-76, 1997.
19. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
20. Hori M and Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension 18: 565-574, 1991.
21. Kilpatrick EL, Narayan P, Mentzer RM Jr, and Lasley RD. Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization. Am J Physiol Heart Circ Physiol 282: H1035-H1040, 2002.
22. Kitakaze M and Hori M. Adenosine therapy: a new approach to chronic heart failure. Exp Opin Investig Drugs 9: 2519-2535, 2000.
23. Linden J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 15: 298-306, 1994.
24. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, and Holmes EW. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99: 1422-1425, 1999.
25. McMurray J and Pfeffer MA. New therapeutic options in congestive heart failure: Part I. Circulation 105: 2099-2106, 2002.
26. Mirabet M, Mallol J, Lluis C, and Franco R. Calcium mobilization in Jurkat cells via A2b adenosine receptors. Br J Pharmacol 122: 1075-1082, 1997.
27. Mubagwa K, Mullane K, and Flameng W. Role of adenosine in the heart and circulation. Cardiovasc Res 32: 797-813, 1996.
28. Rodgers KE, Girgis W, St Amand K, Campeau JD, and diZerega GS. Reduction of adhesion formation by intraperitoneal administration of various anti-inflammatory agents. J Invest Surg 11: 327-339, 1998.
29. Schwarz DS, Hutvagner G, Haley B, and Zamore PD. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 10: 537-548, 2002.
30. Shryock JC and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79: 2-10, 1997.
31. 2A receptor agonists. Br J Pharmacol 132: 1017-1026, 2001.
32. Tucker AL and Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 27: 62-67, 1993.
33. Villarreal FJ, Kim NN, Ungab GD, Printz MP, and Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88: 2849-2861, 1993.
34. Wagner DR, Bontemps F, and van den Berghe G. Existence and role of substrate cycling between AMP and adenosine in isolated rabbit cardiomyocytes under control conditions and in ATP depletion. Circulation 90: 1343-1349, 1994.
35. Zhang WW, Koch PE, and Roth JA. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques 18: 444-447, 1995.